Reed's Remarkable Rant: A Conversation About Cure, Not Celebrity Status
When we last sat down with Reed Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was still in its infancy. The venture outfit had just emerged from the pandemic crash, and biotech was reeling from a prolonged period of market turmoil. Now, Yosemite boasts an impressive roster of 17 employees and is working on a cluster of blockbuster drugs that are all losing patent protection in roughly the same timeframe.
The rapid growth of Yosemite's team has been nothing short of remarkable. Jobs attributed his organization's accelerated progress to a shift in focus away from celebrity status and towards delivering cutting-edge technology that addresses real-world problems. "I didn't expect Yosemite to be moving this fast," he said with a wry smile. The venture outfit's pivot appears to have paid off, as AI has taken on an increasingly prominent role in its work.
As Jobs continued to rattle off the various initiatives and projects currently underway at Yosemite, it became clear that the firm is more than just a speedster; it's a force for good in the biotech landscape. The company's commitment to innovation and problem-solving has earned it recognition from within the industry, with many experts praising its approach as refreshingly humble and unafraid to challenge conventional wisdom.